Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ELVN Enliven Treateutics

Pre-Mkt 01-23 04:40:48 EST

27.03

-0.17

-0.64%

High28.69	Low26.99	Vol1.47M
Open27.73	D1 Closing27.21	Amplitude6.25%
Mkt Cap1.60B	Tradable Cap946.04M	Total Shares59.35M
T/O40.71M	T/O Rate4.19%	Tradable Shares35.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":27.03,"timestamp":1769115600000,"preClose":27.205,"halted":0,"volume":1466778,"delay":0,"changeRate":-0.006432641058628824,"floatShares":34999600,"shares":59347317,"eps":-1.814739,"marketStatus":"Pre-Mkt","change":-0.175,"latestTime":"01-23 04:40:48 EST","open":27.73,"high":28.69,"low":26.99,"amount":40713220.535646,"amplitude":0.062489,"askPrice":29.58,"askSize":30,"bidPrice":23.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.814739,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769178600000},"marketStatusCode":1,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":27.03,"postHourTrading":{"tag":"盘后","latestPrice":27.3281,"preClose":27.03,"latestTime":"18:01 EST","volume":9909,"amount":268000.63,"timestamp":1769122900669,"change":0.2981,"changeRate":0.011028,"amplitude":0.016648},"volumeRatio":1.2827236944270974,"impliedVol":0.4038,"impliedVolPercentile":0.264},"requestUrl":"/m/hq/s/ELVN/tweets","defaultTab":"tweets","newsList":[{"id":"2605381443","title":"Enliven Therapeutics Director Richard A. Heyman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605381443","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2605381443?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:33","pubTimestamp":1769121225,"startTime":"0","endTime":"0","summary":"Richard A. Heyman, Director, reported a disposal of common shares of Enliven Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL7Ll0YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Director Richard A. Heyman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2605443317","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605443317","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605443317?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:35","pubTimestamp":1769121315,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL3yjyfj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2603655751","title":"Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603655751","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603655751?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:54","pubTimestamp":1768344892,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., has reported a disposal of common shares of Enliven Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL1ZPHb2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2603025529","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603025529","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603025529?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:13","pubTimestamp":1768256011,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6Gtb2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2603290175","title":"Enliven Therapeutics Director Richard A. Heyman Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603290175","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603290175?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:11","pubTimestamp":1768255912,"startTime":"0","endTime":"0","summary":"Richard A. Heyman, Director, reported a disposal of common shares of Enliven Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbR6rfc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Director Richard A. Heyman Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2602539564","title":"Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539564","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602539564?lang=en_us&edition=fundamental","pubTime":"2026-01-11 02:16","pubTimestamp":1768069000,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) shares moved after the company released encouraging initial Phase 1b ENABLE data for ELVN-001 in heavily pretreated chronic myeloid leukemia patients who are relapsed, refractory, or intolerant to existing tyrosine kinase inhibitors.\nSee our latest analysis for Enliven Therapeutics.\nThe latest ENABLE readout arrived alongside a board refresh, with industry veteran Scott Garland joining as a director. The stock has been highly reactive. Enliven Therapeutics has seen...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/assessing-enliven-therapeutics-elvn-valuation-after-encourag","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/assessing-enliven-therapeutics-elvn-valuation-after-encourag","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4139","DCF","LENZ","ELVN","BK4539"],"gpt_icon":0},{"id":"2602302161","title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for Director Garland J. Scott","url":"https://stock-news.laohu8.com/highlight/detail?id=2602302161","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602302161?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:04","pubTimestamp":1767999882,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Garland J. Scott as the beneficial owner in his role as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL3CZl28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for Director Garland J. Scott","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2602439631","title":"Analysts Are Bullish on Top Healthcare Stocks: Rubicon Organics (ROMJF), Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602439631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602439631?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:50","pubTimestamp":1767887440,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rubicon Organics (ROMJF – Research Report) and Enliv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-rubicon-organics-romjf-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-rubicon-organics-romjf-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","ELVN","LU0128526141.USD","ROMJF","BK4588","BK4139","BK4007","BK4581","BK4585","LU0029874061.USD","XBI","BK4137","BK4539","LABU"],"gpt_icon":0},{"id":"2601952733","title":"Enliven Therapeutics Up Over 58%, on Pace for Largest Percent Increase Since September 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601952733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601952733?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:48","pubTimestamp":1767887280,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics, Inc.  is currently at $24.52, up $9.05 or 58.5%. --Would be highest close since Dec. 6, 2024, when it closed at $25.42. --On pace for largest percent increase since Sept. 7, 2022, when it rose 71.79%. --Currently up two consecutive days; up 61.96% over this period. --Down 88.83% from its all-time closing high of $219.48 on June 11, 2020. --Up 1.53% from 52 weeks ago , when it closed at $24.15. --Up 64.45% from its 52-week closing low of $14.91 on April 10, 2025. --Traded as high as $25.59; highest intraday level since Dec. 9, 2024, when it hit $25.67. --Up 65.42% at today's intraday high; largest intraday percent increase since Sept. 7, 2022, when it rose as much as 74.36%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007","ELVN"],"gpt_icon":0},{"id":"2601393978","title":"Enliven Therapeutics Shares Surge on Positive Initial Data for Leukemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601393978","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601393978?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:03","pubTimestamp":1767884580,"startTime":"0","endTime":"0","summary":"Shares of Enliven Therapeutics were sharply higher after the biotechnology company reported positive initial data from a Phase 1b trial for a leukemia treatment.The stock was up 61% at $24.95 in Thursday morning trading. Shares have stayed roughly flat over the past year.Enliven said the treatment, ELVN-001, had a cumulative major molecular response rate of 69% by 24 weeks among patients with chronic myeloid leukemia that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors.Enliven Chief Medical Officer Helen Collins said the company is preparing to work with the Food and Drug Administration to initiate a Phase 3 trial in the second half of the year.\"We are excited about these initial Phase 1b data, the progress we made throughout 2025 and the year ahead,\" Collins said. \"Our data continue to demonstrate that ELVN-001 has the potential to be the best-in-class active-site TKI for the treatment of CML and an important treatment option across all lines of therapy.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ELVN","BK4139","BK4539","BK4007"],"gpt_icon":0},{"id":"2601792367","title":"Enliven Therapeutics Reports Positive Phase 1b Results for ELVN-001 in CML","url":"https://stock-news.laohu8.com/highlight/detail?id=2601792367","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601792367?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:01","pubTimestamp":1767880900,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. announced positive initial data from its ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia  who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors. As of December 22, 2025, 60 patients were enrolled across different dosing cohorts. The cumulative major molecular response  rate was 69% by 24 weeks, with 53% of patients achieving MMR within that period. ELVN-001 demonstrated a favorable safety and tolerability profile across all tested doses, with no new safety signals identified. Additional Phase 1 data are expected to be presented mid-2026, and the company plans to align with the FDA on dose selection and initiate a Phase 3 trial in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL17hNgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2601033801","title":"BRIEF-Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601033801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601033801?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797230,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026 Jan 7 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS INC - CONTINUES TO PREPARE FOR PHASE 3 TRIAL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y8167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2601098628","title":"Enliven Therapeutics Inc - Continues to Prepare for Phase 3 Trial Initiation in 2026 and the Commercialization of Elvn-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2601098628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601098628?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:06","pubTimestamp":1767794768,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y8167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2601806733","title":"Enliven Therapeutics Appoints Scott Garland to Board as Andrew Phillips Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806733","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806733?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:01","pubTimestamp":1767794518,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has appointed Scott Garland to its Board of Directors as the company prepares for late-stage development and potential commercialization of ELVN-001. Andrew Phillips, Ph.D., will step down from the Board, effective January 7, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL9qxPJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2601806702","title":"Press Release: Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806702?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:00","pubTimestamp":1767794400,"startTime":"0","endTime":"0","summary":"Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors. Building on positive data reported in 2025, Enliven continues to prepare for Phase 3 trial initiation in 2026 and the commercialization of ELVN-001. BOULDER, Colo., Jan. 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Scott Garland to its Board of Directors and the planned resignation of Andrew Phillips, Ph.D., who has decided to step down, effective January 7, 2026, as the Company transitions its focus to late-stage development and commercialization.\"We are pleased to welcome Scott Garland to our Board at this next stage of Enliven's development. Scott brings vast experience spanning oncology and hematology commercialization at both big pharma and early commercial-stage bio","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ELVN","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2593449414","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593449414","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593449414?lang=en_us&edition=fundamental","pubTime":"2025-12-24 07:45","pubTimestamp":1766533558,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL8FTnrv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2591125666","title":"Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591125666","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591125666?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:18","pubTimestamp":1765779487,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) just reshuffled its top ranks, naming industry veteran Richard Fair as CEO, President, and board member, while co founder Sam Kintz shifts to Head of Pipeline to focus on R and D.\nSee our latest analysis for Enliven Therapeutics.\nThe leadership shake up lands after a rough stretch for the stock, with a 7 day share price return of minus 22.7 percent and a 1 year total shareholder return of minus 27.17 percent. This suggests momentum has been fading despite the late...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4139","LENZ","ELVN","BK4007"],"gpt_icon":0},{"id":"2591728682","title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair","url":"https://stock-news.laohu8.com/highlight/detail?id=2591728682","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591728682?lang=en_us&edition=fundamental","pubTime":"2025-12-13 07:30","pubTimestamp":1765582248,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Richard A. Fair as the beneficial owner, serving as President, CEO, and Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL5cTZTs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590557541","title":"Enliven Therapeutics Grants CEO Richard Fair Stock Option Inducement Package","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557541","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590557541?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:22","pubTimestamp":1765488151,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has granted an inducement stock option to Richard Fair, the company's new President and Chief Executive Officer. Fair received an option to purchase 875,000 shares of Enliven's common stock at an exercise price of $18.77 per share, which was the closing price on the grant date. The option will vest with 25% of the shares vesting on the first anniversary of the grant, and the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 11, 2025, and is solely responsible for the information","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7SYxdz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2590541328","title":"Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541328?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:22","pubTimestamp":1765488140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUAJLSL9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imaratx.com","stockEarnings":[{"period":"1week","weight":0.0739},{"period":"1month","weight":0.6352},{"period":"3month","weight":0.3115},{"period":"6month","weight":0.275},{"period":"1year","weight":0.2259},{"period":"ytd","weight":0.7552}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.033164},{"month":2,"riseRate":0.6,"avgChangeRate":0.039232},{"month":3,"riseRate":0.6,"avgChangeRate":-0.005968},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.083053},{"month":5,"riseRate":0.333333,"avgChangeRate":0.166061},{"month":6,"riseRate":0.833333,"avgChangeRate":0.03326},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.105586},{"month":8,"riseRate":0.5,"avgChangeRate":-0.03666},{"month":9,"riseRate":0.5,"avgChangeRate":0.118476},{"month":10,"riseRate":0.5,"avgChangeRate":0.124766},{"month":11,"riseRate":0.166667,"avgChangeRate":0.036396},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.10748}],"exchange":"NASDAQ","name":"Enliven Treateutics","nameEN":"Enliven Treateutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enliven Treateutics,ELVN,Enliven Treateutics股票,Enliven Treateutics股票老虎,Enliven Treateutics股票老虎国际,Enliven Treateutics行情,Enliven Treateutics股票行情,Enliven Treateutics股价,Enliven Treateutics股市,Enliven Treateutics股票价格,Enliven Treateutics股票交易,Enliven Treateutics股票购买,Enliven Treateutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enliven Treateutics(ELVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enliven Treateutics(ELVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction